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Percutaneous treatment of peripheral vascular
disease: The role of diabetes and inflammation
Louis L. Nguyen, MD, MBA, MPH, Boston, Mass
Peripheral arterial disease (PAD) is a growing health problem for many Americans and often occurs along with other
cardiovascular risk factors, including diabetes mellitus (DM), low-grade inflammation, hypertension, and lipid disorders.
Intermittent claudication (IC), an early manifestation of PAD, commonly leads to reduced quality of life for patients who
are limited in their ambulation. While recent wide adoption of percutaneous peripheral interventional (PPI) techniques
has increased the number patients being aggressively treated for IC, the overall effectiveness of PPI for the treatment of
IC is not well known, especially for DM patients who have both hemodynamic and functional obstacles to treatment
success. This review is designed to illustrate how treatment outcomes for IC can be measured by different modalities and
how diabetes and inflammation can influence those outcomes. In the setting of greater concern for health care resources
and clinical accountability, better understanding of treatment outcomes and efficacy will help us manage these complex
challenges. ( J Vasc Surg 2007;45:149A-157A.)Peripheral arterial disease (PAD) is a growing health
problem for many Americans. The burden of PAD often
occurs along with other cardiovascular risk factors, includ-
ing diabetes mellitus (DM), low-grade inflammation, hy-
pertension, and lipid disorders. DM, in particular, is an
increasingly important cofactor because the number of
PAD patients with DM continues to increase. Intermittent
claudication (IC), an early manifestation of PAD, com-
monly leads to reduced quality of life (QOL) for patients
who are limited in their ambulation. The recent wide
adoption of percutaneous peripheral interventional (PPI)
techniques has increased the number patients being aggres-
sively treated for IC. However, the overall effectiveness of
PPI for the treatment of IC is not well known, especially for
DM patients who have both hemodynamic and functional
obstacles to treatment success.
From a functional standpoint, DM patients fre-
quently have coexisting impairments, such as neuropathy
and obesity, that may negatively impact on walking
rehabilitation and QOL after PPI. They also have a
greater risk of cardiovascular-related morbidity and mor-
tality, perhaps leading to more compromised benefit
from PPI. Thus, the risk–benefit ratio for treatment of
IC in DM patients is particularly complex and not well
understood.
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doi:10.1016/j.jvs.2007.02.029Recent attention has also focused on the prediabetic
spectrum of impaired glucose metabolism, with a growing
population of patients identified with insulin resistance
(IR), impaired glucose tolerance, and obesity. Hypertri-
glyceridemia, IR, decreased high-density lipoprotein cho-
lesterol, hypertension, and central obesity are clustered
factors known as “metabolic syndrome,” which portends
increased cardiovascular risk. Impaired fibrinolysis and low-
grade inflammation are also associated with the metabolic
syndrome and may act as comodifiers that predispose the
patient to cardiovascular disease and affect hemodynamic
outcomes after PPI, such as early failure or restenosis.
Patients with PAD have a higher prevalence of DM, IR,
and inflammatory markers, and the interplay of these fac-
tors is currently under investigation. Their role as a predic-
tor or effecter of treatment outcomes also needs to be
analyzed using several different outcomemeasures to better
capture their impact on the patients being treated.
BACKGROUND AND SIGNIFICANCE
Claudication. PAD, a chronic, progressive disease of
arterial obliteration most commonly due to atherosclerosis,
affects approximately 8 to 10 million Americans, up to half
of whom have symptomatic disease.1,2 IC usually is the first
symptomatic presentation of PAD. Patients with IC have
limited ambulation distance or speed due to pain. This
impairment in function results in a reduction in QOL.
Patients with IC have traditionally been treated with
conservative medical management, including a walking
program, smoking cessation, and risk factor reduction.3,4
Current pharmacologic therapies for IC have modest re-
sults. Pentoxifylline, a xanthine derivative, improves red cell
deformity, lowers fibrinogen levels, and decreases platelet
aggregation. Trial patients had a 50% improvement in the
percentage change in absolute walking distance compared
149A
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was not statistically significant.5 No patient questionnaires
were used in this trial to assess clinical efficacy.
Cilostazol is a phosphodiesterase III inhibitor with
antiplatelet and vasodilation effects. Controlled trials
showed statistically improved walking distance in study
patients (47% vs 13%).6 In these and other trials, the
improvements seen in the control groups suggest that the
placebo effect may be a contributor to outcomes. The
current evidence is not sufficient to recommend the routine
use of pharmacotherapy in all patients with IC.2
Traditionally, those who did not improve with these
medical strategies or who were severely debilitated from
their IC were revascularized with surgical bypass grafting.7
Conservative approaches to IC are based in part on data
that suggested few patients progressed to worsening PAD,
as evidenced by a minimal drop in the ankle-brachial index
(ABI) over 5 years8 and the small number of IC patients
who go on to develop critical limb ischemia (CLI).9 How-
ever, more recent data show that the natural history of
elderly men with IC was a decline in walking and overall
activity.10 These findings highlight a growing understand-
ing that IC has socioeconomic impacts that were previously
not well appreciated.11
Advancements in catheter-based techniques have
added another therapeutic option in the treatment of IC.
PPI are less invasive than open surgical bypass yet restore
vessel patency, unlike pharmacotherapy. The use of PPI in
the treatment of aortoiliac occlusive disease is well estab-
lished.2 Outcomes for infrainguinal PPI for IC are less
known, however, and their applicability to certain patient
populations is controversial. Several issues have made the
treatment of IC a more complex issue:
1. Although a monitored exercise rehabilitation program
can result in improved walking, perceived QOL, and
general physical activity,12,13 many patients cannot
maintain an exercise program, and thus, their symptoms
do not resolve.
2. IC is a symptom resulting from more than just de-
creased blood flow to the lower extremity. Distur-
bances in muscle metabolism,14 and specifically of glu-
cose utilization,15 may also contribute to walking
intolerance in patients with PAD.
3. Patients with lower extremity intervention have a 3.3%
to 8.3% annual incidence of contralateral ischemia16;
therefore, PAD is a two-limb problem and good clinical
outcome requires function of both limbs.
4. Patients with IC are also at greater risk for mortality,
with old age, lower ABI, DM, and stroke among risk
factors.17
Several studies have yielded all-cause mortality rates of 30%
at 5 years and 50% at 10 years, a prognosis equivalent to
postresection of Duke’s B colon carcinoma.2 Thus, the
long-term benefits of IC treatment may be diminished by
the relatively high mortality rates in this cohort.
Arguably, the biggest questions in the treatment in IC
is who, when, and how to treat, and if to treat at all. To bestanswer these questions, a series of large, multi-institutional,
randomized trials would be needed. However, we have
observed in our clinical experience that the treatment of IC
with PPI seems to be driven by other factors in addition to
published practice guidelines based on clinical studies. Eco-
nomic factors, including first-mover advantage, market
share growth, provider specialty competition, and industry
involvement are affecting decisions in the treatment of IC
and, specifically, the use of PPI in that treatment strategy.
Diabetes and insulin resistance in peripheral arterial
disease. The prevalence of DM is rapidly increasing and is
predicted to affect 221 million individuals worldwide by
2010.18 Overall, patients with DM have greater general
disability, including decreased mobility.19 Patients with
DMhave an increased risk of developing PAD, and that risk
increases with the duration of DM.20 Patients with DM and
PAD have impaired mobility due to neuropathy, IC, and
cardiovascular comorbidities.21
People with type 1 DM have autoimmune-mediated
destruction of pancreatic islet cells that results in an abso-
lute insulin deficiency. Type 2 DM is more prevalent is and
characterized by IR or abnormal insulin secretion, or both.
Although some type 2 DM patients may require exogenous
insulin, many may not if glucose control can be achieved
with diet alone or the addition of oral hypoglycemic agents.
Thus, some patients may have a component of IR and be
unaware because of the mildness of symptoms or poor
understanding of infrequent symptoms.
In addition to frankDM, IR occurs in an estimated 22%
of the United States (US) population.22 With IR, impaired
insulin signaling results in decreased utilization of glucose
and fatty acids in skeletal muscles. This results in hypergly-
cemia and increased levels of circulating free fatty acids. In
response to the hyperglycemia, islet cells produce more
insulin, which leads to hyperinsulinemia. The IR syndrome
is the presence of three ormore of the following: abdominal
obesity, high triglyceride levels, low high-density lipopro-
tein cholesterol, hypertension, and hyperglycemia.22 The
National Cholesterol Education Program suggested a sim-
ilar definition for the metabolic syndrome.23
Although the mechanisms of diabetic vascular disease
remain incompletely understood, considerable data suggest
that hyperglycemia itself causes vascular damage. Several
studies have linked both microvascular and macrovascular
complications of DM to the level of glycemic control.
Longstanding hyperglycemia can lead to nonenzymatic
glycation and oxidation of proteins and lipids, resulting in
the accumulation of advanced glycation end products
(AGE). These AGE are thought to interact with receptors
(RAGE) in the vasculature, resulting in activation of mech-
anisms leading to atherosclerosis. RAGE also occurs endo-
genously as a soluble form (sRAGE), which can act as a
binding decoy for the cellular RAGE. A novel treatment
strategy was developed using the soluble extracellular do-
main of the AGE receptor (sRAGE) to bind and inactivate
AGE. In vivo studies showed sRAGE suppressed diabetic
atherosclerosis in a glycemia-independent and lipid-
independent manner.24 Low levels of sRAGE were also
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non-DM men.25
Although IC may represent mild PAD in non-DM
patients, CLI26,27 and amputation28 are more likely to
develop in IC patients with DM. Evidence also shows that
PAD patients with DM are undertreated medically29; how-
ever, it is not known which is the cause and which the effect
in these observations. Patients with DM are also less likely
to present with IC as a herald for later CLI.30 Similarly, IR
is associated with atherosclerosis and predicts cardiovascu-
lar events.31,32
Inflammation in peripheral arterial disease. The
role of inflammation in PAD is becoming increasingly
recognized, as is the synergism between inflammation,
DM, and IR. Several inflammatory markers have been
found to be associated with atherosclerosis and related
events, including C-reactive protein (CRP), interleukin
(IL)-6,33 tumor necrosis factor-,34 P selectin,35 soluble
intracellular adhesion molecule-1 (sICAM-1), soluble vas-
cular cell adhesion molecule-1 (sVCAM-1), CD40 ligand,
and E selectin.36
CD40 ligand is a transmembrane protein expressed on
a variety of cells, including endothelial cells, vascular
smooth muscle cells, and activated platelets. It is also found
in plasma as a soluble protein, sCD40 ligand. CD40 ligand
binding to its receptor, CD40, results in initiation of in-
flammatory responses.37 Elevated sCD40 ligand levels have
been associated with increased risk for cardiovascular
events, and intensive risk factor reduction has resulted in
reduction of sCD40 ligand.38 Patients with DM also show
increased CD40 ligand receptor– binding complex.39 One
potential mechanism linking sCD40 ligand to atheroscle-
rosis in DM patients is through hyperglycemia being an
up-regulator of sCD40 ligand, resulting in endothelial
activation and monocyte recruitment to the arterial wall.40
CRP is a long-described inflammatory marker belong-
ing to the pentraxin family of immune response proteins. It
has several functions that can lead to atherosclerotic pro-
gression, including induction of cell adhesion molecule
expression andmediation of low-density lipoprotein uptake
by endothelial bound macrophages.41 In prospective co-
hort studies, CRP was associated with progression of ca-
rotid atherosclerosis42 and severity of atherosclerosis at
various anatomic sites.43 Patients with PAD have elevated
inflammatory markers, including CRP, and their levels
correspond to the level of disease44: control patients, 1.04
mg/L; IC patients, 3.4 mg/L; and CLI patients, 7.17
mg/L. Higher CRP is associated with greater walking
disability as measured by walking tests and functional sur-
veys.45 Inflammatory markers from asymptomatic patients
have been showed to be predictors risk factors for the
development of subsequent PAD.46 Inflammation is re-
lated to endothelial dysfunction, which in turn may con-
tribute to worsening PAD.47 One mechanism for this effect
may be the ability of CRP to reduce endothelial nitric oxide
synthase (eNOS) expression.48
IL-6 is an acute inflammatory cytokine and the princi-
pal inducer of CRP synthesis by the liver. Several studieshave linked levels of IL-6 with traditional cardiovascular
risk factors, including hypertension, smoking, IR,49 and
excess adipose tissue.50 In patients with acute myocardial
infarction, IL-6 levels increase and peak at 36 hours, sup-
porting the role of inflammation after myocardial injury.51
As a predictor among healthy patients, elevated IL-6 levels
have also been shown to be related to increased risk of
cardiovascular events or death independent of CRP and the
presence of traditional cardiovascular risk factors.52
Evidence suggests that low-grade inflammation is
linked to impairments of fibrinolysis.53 Elevated fibrinogen
is associated with greater risk for cardiovascular events such
as stroke and myocardial infarction.54 Tissue plasminogen
activator (tPA) and its inhibitor, plasminogen activator
inhibitor (PAI-1), play a key part in fibrinolysis. PAI-1
inhibits tPA from cleaving zymogen plasminogen into its
active form and thus results in elevated fibrinogen levels.
PAI-1 activity is elevated in patients with coronary artery
disease, myocardial infarction, and stroke.55,56 Less is
known about the role of fibrinolysis in PAD. Elevated
PAI-1 is associated with PAD57 and with worsening de-
grees of claudication.58 Exercise has been shown to lower
PAI-1 levels in patients with IC,59 though it is not clear
whether increased blood flow from an intervention would
lead to the same reduction.
The mechanism of interaction between DM and in-
flammation in PAD is controversial. DMmay accelerate the
progression of atherosclerosis or act through other separate
pathways. Increased inflammatory markers in healthy pa-
tients may also be predictive of greater risk in the later
development of DM or insulin-resistance syndrome.60 In-
sulin has been shown to have anti-inflammatory effects
through mechanisms mediated by nitric oxide.61,62 Ros-
iglitazone, a thiazolidinedione used in the therapy of type 2
DM, also has anti-inflammatory effects.63 Patients with
elevated CRP and hyperglycemia (as indicated by hemoglo-
bin A1c) are at greater risk for the occurrence of major
adverse cardiovascular events, which include myocardial
infarction, percutaneous coronary interventions, coronary
bypass graft, carotid revascularization, stroke, and death.64
Peripheral angioplasty and stenting. Advances in
percutaneous interventional techniques have allowed clini-
cians to offer therapeutic treatment without the more inva-
sive nature and longer recovery time of open bypass. In
essence, the threshold of invasive treatment has been low-
ered because the new treatment modality is perceived to be
less costly to the patient. The efficacy of aortoiliac angio-
plasty and stenting is well accepted, but the role of PPI in
infrainguinal disease is less established.
Technical and anatomic considerations for catheter-
based therapies are more challenging in the superficial
femoral artery (SFA) and popliteal vessels compared with
more proximal arteries. Initial reports of outcomes for
balloon angioplasty alone in these vessels generally dis-
played inferior outcomes. Improvements in technology,
including the use of nitinol stents and perhaps drug-eluting
stent designs, as well as plaque debulking techniques, are
under continuous evolution.
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primary patency of 30% to 58%, although secondary pa-
tency rates were modestly better at 64% to 72%.65-67 No
difference in outcomes was found for sirolimus-eluting vs
bare metal nitinol stents for SFA disease.68
The TransAtlantic Inter-Society Consensus (TASC)
document is the result of collaborative efforts by multiple
medical specialties to better define standards for manage-
ment of PAD patients and the reporting of outcomes.2 The
TASC classification of femoropopliteal disease is based on
the severity, length, number, and location of lesions
(Table). TASC treatment recommendations for IC are well
defined for the extreme groups: endovascular treatment for
TASC A and surgery for TASC D in appropriately selected
candidates. The treatment for TASC B and C groups is not
as well defined, however. For TASC A and B lesions, some
have found SFA stenting to be comparable with surgical
bypass.69 Stenting results for more severe SFA lesions
showed lower long-term patency than surgery, but second-
ary interventions can be an adjunct in these patients.70
Recent retrospective studies looking at the combined use of
PCI and open revascularization methods for IC show im-
proved outcomes.71
The need for reintervention after PPI should not be
taken lightly, however, because PPI does have a risk of
procedural complications, including access site thrombosis
or hemorrhage, lesion thrombosis or embolization, and
contrast nephropathy.72,73 Potential long-term complica-
tions, such as accelerated progression of disease, remain
unclear.
The outcome of PPI in DM patients is not well known.
Some authors have found no difference in outcomes for
DM patients undergoing femoropopliteal PPI,69,74
whereas others have found worse outcomes in DM pa-
tients. Long femoropopliteal stenting has poor mid-term
patency results, especially in patients with DM.75 Patients
with higher exogenous insulin levels (as measured by lower
C-peptide/insulin ratio) were at greater risk for restenosis
after femoral percutaneous transluminal angioplasty
(PTA).76 A more substantial amount of similar evidence of
worse outcomes can be found for DM patients undergoing
Table. TransAtlantic Inter-Society Consensus (TASC)
morphologic stratification of femoropopliteal lesions
Classification Criteria
TASC A Single stenosis 3 cm long
TASC B Single stenosis or occlusion 3-10 cm long or
Multiple stenoses or occlusions each 3 cm
long
TASC C Single stenosis or occlusion longer than 5cm or
Multiple stenoses or occlusions each 3-5 cm
long
TASC D Complete CFA or SFA occlusion or
Complete popliteal and trifurcation
occlusionpercutaneous coronary intervention (PCI).77,78 Evidencealso suggests that rosiglitazone reduces in-stent restenosis
in DM patients undergoing PCI.79
Likewise, the effect of systemic inflammation on PPI
outcomes is not well known. Stent placement induces
neointimal proliferation through stent struts by means of
local inflammation.80 Measurements of systemic inflamma-
tory markers show conflicting results, however. Some au-
thors have found increased CRP and IL-6 levels after renal
artery stenting81 and coronary stenting,82 although the
levels were not measured beyond 24 hours. Others found
no evidence that the procedure itself causes significant
inflammation, as measured by white blood cell and endo-
thelial markers.83 It is not clear whether preprocedural
levels of inflammatory markers are predictive of PPI out-
comes.
Functional and quality of life outcomes in periph-
eral arterial disease. Initially, the measurement of success
for percutaneous interventions was defined by anatomic
criteria and vessel patency, but subsequent work has also
focused on patient outcomes such as walking distance,
walking speed,84 and QOL. Indeed, randomized con-
trolled treatment of IC showed patients who received inva-
sive treatment had better walking measurements and toe
pressures after 1 year, whereas supervised exercise training
was similar to untreated controls.85 For IC patients, vessel
patency does not necessarily translate to improvements in
walking or lifestyle, especially for patients who are already
debilitated. Conversely, improvements in walking or life-
style do not imply vessel patency, as demonstrated by a
person who stops smoking. Thus, the measured benefit of
percutaneous intervention for ICmust be a combination of
outcomes.
Patients with IC can present with a wide range of
severity of symptoms. They can have greater perceived
problems with energy, pain, emotional reactions, sleep, and
physical mobility.86 As such, the effect of IC on a patient’s
QOL depends on several baseline factors: walking distance
and intensity, overall general activity, and the presence of
other factors that reduce QOL. Two surveys, Walking
Impairment Questionnaire (WIQ) and the EuroQol
Group’s EQ-5D instrument have been widely used to
measure functional and QOL outcomes for IC patients.
The WIQ was developed to measure patient-perceived
walking performance for patients with PAD and IC specif-
ically.87 It estimates IC severity, walking distance, walking
speed, and stair climbing ability. Among its benefits is ease
of use compared with treadmill testing. Furthermore,
treadmill testing may not be reflective of actual daily walk-
ing activities that are more specifically captured in WIQ.
The WIQ scores do, however, correlate with established
walking tests, such as the 6-minute walking distances and
4-meter walking velocity.88
The EQ-5D survey measures health outcomes and has
been validated in a variety of disease conditions and geo-
graphic populations, including patients with IC89 and US
residents.90-92 Its advantage is it is simple, is a quick survey
to administer, and results in a single score. The survey
consists of five questions about mobility, self-care, usual
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on the EQ-5D were seen to increase (0.57 to 0.75) in
patients undergoing revascularization93 and aortoiliac
stenting.94 Transformation of patient results to health util-
ities can be made using known, published reference data
appropriate to the study population.
Conservative management of IC has been shown to be
effective. Monitored walking and exercise programs can
result in symptomatic and functional improvements as mea-
sured by Short Form 36 Health Survey (SF-36) and
WIQ.95 However, many patients do not complete moni-
tored exercise programs because of logistic or medical
limitations and therefore may not gain the QOL described
in large studies.
The measurement of functional improvements as
measured by walking distance, walking speed, and stair
climbing in patients treated for IC has been well docu-
mented.95,96 The improvement of QOL is more difficult
to measure, however, and cannot be directly inferred from
standard vascular anatomic and physiologic results. For
example, health-related QOL as measured by SF-36 and
WIQ is not reflected well by ABI alone.97 Similarly, im-
provements in QOL after IC treatment of any kind did not
correlate with changes in ABI.98 In some patients, stability
in claudication symptoms may be due to decreased activity
rather than to disease stability.99 Even at the initial evalua-
tion point by vascular providers, correlation is lacking be-
tween the patient’s QOL and the physician’s impression of
the symptoms and physical findings.100 This evidence fur-
ther supports the need for the combined use of clinical and
QOL measurements in assessing the impact of PAD and its
treatment.
Cost-effectiveness outcomes in peripheral arterial
disease. Cost-effectiveness analysis seeks to compare two
or more strategies. The evaluation is based on identifying
costs for each strategy and its resulting outcomes while
comparing it to its benefits standardized to a single health
unit, such as quality-adjusted life-years (QALY). Previous
work in determining the cost-effectiveness of treatment
strategies for IC has showed mixed results. De Vries et al101
found that revascularization, defined as surgical bypass or
PPI, was more cost-effective than exercise rehabilita-
tion.101 In contrast, Treesak et al102 found that exercise
was more cost-effective than PTA, and Ambrosetti et al12
found that exercise programs meet acceptable cost-benefit
figures.12 The outcomes of specific invasive treatment de-
cisions are also complex. For the iliac arteries, Bosch et
al103,104 found stenting to be more cost-effective than PTA
alone.103,104 For the SFA, Greenberg et al105 found no
cost-benefit increase for stenting compared to PTA alone,
and Visser et al106 found PTA was as cost-effective as
bypass.
Most cost-effectiveness analyses have used data from
different institutions to build Markov models.101,103,107
Patients from different institutions are likely to differ in
demographics, risk factors, and socioeconomic values, and
are subject to regional or institutional practice patterns.
Treatment costs also vary significantly with the frequency ofprocedure-related complications.108 The complication rate
depends on institutional expertise and the case-risk mix of
patients at the institution; thus, data from studies of differ-
ent patient groups may not be transferable.
Cost-effective ratios largely depend on the health val-
ues of different conditions. These health values may be
affected by the concomitant burden of disease from other
comorbidities. Thus, a patient with IC as the sole disability
is likely to value its treatment differently than a patient with
IC among many other disabilities.
The applicability of cost-effectiveness analysis cannot
be applied to all patients, because subsets of patients may
have different risks and benefits from the same procedure.
Cost-effective ratios represent a weighted average of differ-
ent health states. Individual patients have specific risk fac-
tors that may not be well represented in the weighted
averages. Hunink et al107 found that from a cost-effective
standpoint, angioplasty is the preferred initial treatment for
all patients with lower extremity ischemia, except for pa-
tients with CLI and femoropopliteal occlusion, where sur-
gical bypass is the preferred treatment. The identification of
significant patient factors or clinical scenarios that may have
significantly different cost-benefit ratios is an important
step in the practical applicability of cost-effectiveness anal-
ysis.
The applicability of cost-effectiveness analysis can vary
for different institutions and time periods. Institutional
size, patient volume, and treatment patterns vary signifi-
cantly, so it follows that their costs do as well. Conclusions
from older studies may no longer be as accurate because of
advancements in technology, changes in costs, and changes
in patient characteristics. Nevertheless, understanding rel-
ative cost differences between treatment strategies or pa-
tient groups can help practitioners and policy-makers better
address resource allocation issues.
As a whole, cost-effectiveness analyses have increased
our understanding of the implications of complex clinical
treatment decisions. For a variety of reasons, however,
actual clinical practice patterns do not usually comply
with cost-effective recommendations. Conflicting cost-
effectiveness analysis results, poor applicability, dated
costs, and technologic innovation may be among the
potential reasons why clinicians make decisions contrary
to cost-effectiveness analysis results. As well, cost-effec-
tiveness analysis is based on two or more treatment strate-
gies rather than patient factors. The available choice of
strategies is the focus of cost-effectiveness analysis.
Patient factors are not immutable either, however. Al-
though a physician cannot implicitly choose DM as a risk
factor for a patient, the physician can choose to modify the
severity of the risk factor, or the medical field as a whole can
choose to focus more resources on the prevention or reduc-
tion of DM. Similarly, physicians do not intentionally
choose to give their patients a postoperative complication,
but it is important to recognize that patients with seemingly
minor postoperative complications can have radically al-
tered prognosis.109 Thus, cost analysis for the effect of
specific patient factors, namely DM, may identify cost-
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and patient outcomes.
Background summary. As the number of active el-
derly Americans increases, IC will become a more impor-
tant factor in limiting lifestyle and affecting QOL. The
treatment of IC has changed in recent years. It is likely that
more IC patients are being treated with invasive techniques
because the perceived risk-benefit threshold has lowered
with the adoption of PPI techniques. Similarly, the number
of patients with IR or frank DM is also increasing, and a
subset of them will present initially with IC.
Some early evidence supports infrainguinal PPI for the
treatment of IC, but outcomes for patients with DM are
not as clear. Furthermore, the role of inflammation in PAD
is becoming increasingly understood in its relationship with
IR. In contrast to most PAD patients, additional biologic
and functional obstacles to PAD treatment success may be
present in DM patients. Accordingly, outcomes of PPI for
DM patients should be measured using hemodynamic,
functional, as well as QOL end points. These three broad
outcome categories are dependent on each other but also
have many nonvascular effectors. For example, QOL de-
pends on hemodynamic and functional success, although
patients who undergo repeated procedure to maintain he-
modynamic success might have a lower QOL. Similarly,
patients who are burdened with significant comorbidites
might not enjoy the functional benefits of hemodynamic
success. We see outcomes for PPI as a continuum of differ-
ent measures that better quantify the benefit to the patient
and the health care system. DM, IR, and inflammatory
markers are just a few of the factors that influence these
outcomes at several levels (Fig).
Nationally, the treatment of IC with PPI may be in-
creasing because of several factors, including steady devel-
opment of new technology, practice of PPI among differ-
ent competing medicine specialty groups, and a perceived
better risk-benefit profile. The impact of widespread PPI
use on patient outcomes and the health care system is not
well known, however. The subgroup of DM or IR patients
with elevated inflammatory markers may also have different
outcomes than the general population. Therefore, current
national practice patterns for IC should be examined with
attention to critical risk factors and potential diminished
outcomes.
Fig. Levels of outcomes for percutaneous peripheral interven-
tions.ONGOING RESEARCH
To address some of the issues of the effect of DM and
inflammation on outcomes of PPI, we have recently begun
a National Institutes of Health–funded study of such pa-
tients at our institution. We hypothesize that DM and IR
are cofactors that confer greater risk for PPI treatment
failure for IC, as measured by hemodynamic, functional
and QOL outcomes. To test this hypothesis, a prospective,
longitudinal cohort study is being conducted to acquire
anatomic, biomarker, medical, cost accounting, functional,
and QOL data for patients undergoing PPI of the femoro-
popliteal segment for treatment of IC. Our specific aims are
to analyze the association of DM, IR, and inflammatory
markers with (1) “traditional” vascular anatomic outcomes
(vessel patency, reintervention, limb loss), (2) functional
walking performance (treadmill test), and (3) QOL (as
measured by WIQ and EQ-5D). Complex multivariable
modeling will be used to analyze relationships between risk
factors and outcomes. Cost analysis will highlight critical
cost-sensitive factors or events in the patient care process.
Large national databases will be used to examine secular
trends in the treatment of IC and extend the implications of
the results seen in this study.
Although the individual outcome measures used in our
study have been used elsewhere, we believe that the inter-
relationship between these different measures of treatment
success has not been studied systematically, especially in the
background of significant medical comorbidities such as
DM and inflammation. Identifying correctable factors or
understanding the influence of uncorrectable factors will
allow us to improve treatment outcomes. At the same time,
better understanding of how to measure those outcomes
will allow us to improve their positive impact on the patient.
CONCLUSIONS
The growth of percutaneous vascular interventional
techniques has resulted in many unanswered questions that
require novel studies and analytic techniques. One group of
questions deals with determining the outcomes of interven-
tions and the influence of commonly prevalent risk factors.
A second set of questions deals with measuring QOL and
other socioeconomic outcomes that have not been well
measured. For lifestyle-limiting conditions such as claudi-
cation, QOL and overall functional status are important
outcomes not well captured by tradition measurements
such as survival and limb salvage. Finally, with the rapid
development and adoption of technology in all medical
fields, the long-term impact to the health care system needs
to be examined in light of decreasing national resources.
We believe that clinical trials should be complemented
by more general inquiries into financial and policy implica-
tions. Likewise, policy research in isolation cannot entirely
guide the care of patients because of the inherent individual
complexity and variation of patients. Clinical physicians
who are also trained in health services research can bridge
the gap between innovative clinical practice and the effect
of technology on the health care system. This “outcomes
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for the basic sciences, will extend the application of new
technologies and techniques to better fit with the changing
socioeconomic demands in health care.
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